Related Experiment Video

Updated: Aug 19, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and

Henry F Chambers1

  • 1Division of Infectious Diseases, San Francisco General Hospital, and University of California--San Francisco, Room 3400, Building 30, 1001 Potrero Ave., San Francisco, CA 94110, USA. chipc@itsa.ucsf.edu

Antimicrobial Agents and Chemotherapy
|February 25, 2005
PubMed

Insights

Ceftobiprole shows promise against drug-resistant Staphylococcus aureus. This novel cephalosporin demonstrated effectiveness in a rabbit model, suggesting potential for treating resistant infections.

Area of Science:

  • Pharmacology and Microbiology
  • Infectious Diseases

Background:

  • Emergence of antibiotic resistance in Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
  • Need for novel antibiotics with broad-spectrum activity against resistant bacterial strains.

Purpose of the Study:

  • To evaluate the efficacy of ceftobiprole compared to vancomycin.
  • To assess treatment in a rabbit model of aortic valve endocarditis caused by drug-resistant Staphylococcus aureus strains.

Main Methods:

  • Utilized a rabbit model of aortic valve endocarditis.
  • Infection was induced by Staphylococcus aureus strains, including MRSA and VISA.
  • Ceftobiprole efficacy was directly compared to vancomycin treatment.

Main Results:

  • Ceftobiprole and vancomycin exhibited comparable efficacy against MRSA strain 76.
  • Ceftobiprole demonstrated superior effectiveness compared to vancomycin against VISA strain HIP5836.
  • Ceftobiprole displayed significant activity against both methicillin- and vancomycin-resistant Staphylococcus aureus.

Conclusions:

  • Ceftobiprole is an effective therapeutic option against challenging Staphylococcus aureus infections.
  • Its activity against resistant strains supports further clinical investigation and development.
  • Ceftobiprole represents a potential advancement in managing infections caused by multidrug-resistant bacteria.

More Related Videos

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection09:09

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection

Published on: March 14, 2019

In Vivo Mouse Model of Spinal Implant Infection08:03

In Vivo Mouse Model of Spinal Implant Infection

Published on: June 23, 2020

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...